2024
Describing the genomic landscape of bladder cancer histologic subtypes.
Talukder R, Berg R, Huang M, Nepomucino V, Stoppler M, Makrakis D, Yen A, Mims M, Lerner S, Woldu S, Lotan Y, Yu E, Khaki A, Aragon-Ching J, Grivas P. Describing the genomic landscape of bladder cancer histologic subtypes. Journal Of Clinical Oncology 2024, 42: 680-680. DOI: 10.1200/jco.2024.42.4_suppl.680.Peer-Reviewed Original ResearchHistological subtypes of bladder cancerSquamous cell differentiationSubtypes of bladder cancerSmall cell/neuroendocrineHistological subtypesBladder cancerGenomic alterationsOverall cohortPD-L1-positive statusDiagnosis of bladder cancerAssociated with poor prognosisTumor mutational burdenGenomic landscapeCancer histological subtypesGenomic alteration patternsClinical trial designCopy number variantsMSI-high statusKruskal-Wallis testPD-L1Immunotherapy biomarkersERBB2 amplificationMutational burdenMedian ageTherapy resistance
2023
Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.
Fanucci K, Lustberg M, Fischbach N, Pelletier M, Sivapiragasam A, Ashok Kumar P, Kallem M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study. Journal Of Clinical Oncology 2023, 41: 1036-1036. DOI: 10.1200/jco.2023.41.16_suppl.1036.Peer-Reviewed Original ResearchMetastatic breast cancerLobular histologyBreast cancerHER2 IHCGenomic alterationsComprehensive genomic profiling studyPD-L1 gene amplificationImmune checkpoint inhibitor treatmentMicrosatellite instabilityAxillary LN metastasisMetastatic site biopsySubset of ptsStage IV diseaseCheckpoint inhibitor treatmentPD-L1 expressionTumor mutational burdenMutations/MbMSI-high statusHER2 IHC resultsGenomic profiling studiesSite biopsiesSP142 assayLN metastasisMetastatic diseaseHigh TMB
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply